Peroxisome Proliferator-activated Receptors and Hepatic Stellate Cell Activation
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
The present study examined the roles of peroxisome proliferator-activated receptors (PPAR) in activation of hepatic stellate cells (HSC), a pivotal event in liver fibrogenesis. RNase protection assay detected mRNA for PPARgamma1 but not that for the adipocyte-specific gamma2 isoform in HSC isolated from sham-operated rats, whereas the transcripts for neither isoforms were detectable in HSC from cholestatic liver fibrosis induced by bile duct ligation (BDL). Semi-quantitative reverse transcriptase-polymerase chain reaction confirmed a 70% reduction in PPARgamma mRNA level in HSC from BDL. Nuclear extracts from BDL cells showed an expected diminution of binding to PPAR-responsive element, whereas NF-kappaB and AP-1 binding were increased. Treatment of cultured-activated HSC with ligands for PPARgamma (10 microm 15-deoxy-Delta(12,14)-PGJ(2) (15dPGJ(2)); 0.1 approximately 10 microm BRL49653) inhibited DNA and collagen synthesis without affecting the cell viability. Suppression of HSC collagen by 15dPGJ(2) was abrogated 70% by the concomitant treatment with a PPARgamma antagonist (GW9662). HSC DNA and collagen synthesis were inhibited by WY14643 at the concentrations known to activate both PPARalpha and gamma (>100 microm) but not at those that only activate PPARalpha (<10 microm) or by a synthetic PPARalpha-selective agonist (GW9578). 15dPGJ(2) reduced alpha1(I) procollagen, smooth muscle alpha-actin, and monocyte chemotactic protein-1 mRNA levels while inducing matrix metalloproteinase-3 and CD36. 15dPGJ(2) and BRL49653 inhibited alpha1(I) procollagen promoter activity. Tumor necrosis factor alpha (10 ng/ml) reduced PPARgamma mRNA, and this effect was prevented by the treatment with 15dPGJ(2). These results demonstrate that HSC activation is associated with the reductions in PPARgamma expression and PPAR-responsive element binding in vivo and is reversed by the treatment with PPARgamma ligands in vitro. These findings implicate diminished PPARgamma signaling in molecular mechanisms underlying activation of HSC in liver fibrogenesis and the potential therapeutic value of PPARgamma ligands for liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![FIG. 4 A , PPAR g (15dPGJ2, BRL49653) ligands inhibit HSC DNA and collagen synthesis. The 3-4-day primary cultures of HSC were exposed to 15dPGJ2 (1 and 10 m M), BRL49653 (1 and 10 m M), or WY14643 (10 ; 250 m M) for 18 h, and [ 3 H]thymidine incorporation into DNA was assessed. Note a significant, ; 40%, inhibition in HSC DNA synthesis by 15dPGJ2 and BRL49653 at 10 m M and WY14643 at 100 and 250 m M. *, p , 0.05; **, p , 0.01 compared with the respective control. DMSO , Me2SO. B , collagen production by cultured HSC, as determined by incorporation of [ 3 H]proline into collagenase-sensitive peptides was significantly inhibited by 18 h of treatment with 15dPGJ 2 (10 m M), BRL49653 (0.1 ; 10 m M), and WY14643 (100 m M). *, p , 0.05; **,](https://figures.cochat.ai/paper-figures/a66e36c4743842c5bde9349747bed49a/peroxisome-proliferator-activated-receptors-and-hepatic-stellate-cell-activation-figure-4.png)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“bezafibrate, a broad peroxisome proliferator-activated receptor (PPAR) agonist with anticholestatic, 14 anti-inflammatory, 15 and antifibrotic 16 properties”
From Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial (2021) · cites this paper as [16]
Experimental — accuracy not yet measuredIn the citing paper
“HSC activation is therefore associated with low levels of PPAR-γ expression, and the assumed relation between PPAR-γ and liver fibrosis was confirmed in an experimental restoration of PPAR-γ levels in HSCs, which resulted in a regression of aHSCs to quiescence state.[126,127]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426
Schreiber, E., Matthias, P., Müller, M. M., & Schaffner, W. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.15.6419 · Cited by 4,179
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Self-citationThomas, A. C., & Campbell, J. H. (2000) · Cited by 2,800
A human retinoic acid receptor which belongs to the family of nuclear receptors
Petkovich, M., Brand, N. J., Krust, A., & Chambon, P. (1987) · Nature · doi:10.1038/330444a0 · Cited by 2,214
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816
Self-citationPPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797
The Cellular Basis of Hepatic Fibrosis -- Mechanisms and Treatment Strategies
Flier, J. S., Underhill, L. H., & Friedman, S. L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306243282508 · Cited by 1,432
The PPARα–leukotriene B4 pathway to inflammation control
Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W. (1996) · Nature · doi:10.1038/384039a0 · Cited by 1,345
Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M., & Santoro, M. G. (2000) · Nature · doi:10.1038/47520 · Cited by 1,310
Research works printed but not linked: 9
- Friedman, S. L., Wei, S., and Blaner, W. S. (1993) Am. J. Physiol. 264, G947-G952
- Tsukamoto, H., Cheng, S., and Blaner, W. S. (1996) Am. J. Physiol. 270, G581-G586
- Salbert, G., Fanjul, A., Piedrafita, F. J., Lu, X. P., Kim, S. J., Tran, P., and Pfahl, M. (1993) Mol. Endocrinol. 7, 1347-1356
- Okuno, M., Moriwaki, H., Imai, S., Muto, Y., Kawada, N., Suzuki, Y., and Kojima, S. (1997) Hepatology 26, 913-921
- Potter, J. J., Womack, L., Mezey, E., and Anania, F. A. (1998) Biochem. Cell Biol.244, 178 -182
- Lin, M., Rippe, R. A., Niemela, O., Brittenham, G., and Tsukamoto, H. (1997) Am. J. Physiol. 272, G1355-G1364
- Rippe, R. A., Almounajed, G., and Brenner, D. A. (1995) Hepatology 22, 241-251
- Zhang, B., Berger, J., Hu, E., Szalkowski, D., White-Carrington, S., Spiegelman, B. M., and Moller, D. E. (1996) Mol. Endocrinol. 10, 1457-1466
- Tsukamoto, H. (1999) Alcohol Clin. Exp. Res. 23, 911-916 · doi:10.1111/j.1530-0277.1999.tb04202.x · Paper page
Cited by
Items 301–400 of 477
Zheng, M., Li, Y., Wang, G., Jin, J., Wang, Y., Wang, T.-M., Yang, L., Liu, S., Wu, J., Wang, Z.-T., et al. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108701 · Cited by 26
de Souza, I. C. C., Martins, L. A. M., de Vasconcelos, M., de Oliveira, C. M., Barbé‐Tuana, F. M., Andrade, C. M. B., Pettenuzzo, L. F., Borojević, R., Margis, R., Guaragna, R. M. V. D. C., et al. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25181 · Cited by 27
“…PPARgligands inhibits cell proliferation and the expression of both a-SMA type I collagen and monocyte chemotactic protein 1, a potent chemokine secreted by activated HSC that recruits and activates monocytes and T-lymphocytes [Miyahara et al., 2000; Eng and Friedman, 2001; Hazra et al., 2004].”
BackgroundBae, M., Rhee, S. D., Jung, W. H., Ahn, J. H., Song, B., & Cheon, H. G. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-0313-3 · Cited by 26
“…report showed that PPARγ1 mRNA is expressed in normal HSCs, while it is not detected in the HSCs isolated from livers with cholestatic fibrosis induced by bile duct ligation, suggesting an inverse relationship between PPARγ1 and fibrosis (i.e., stellate cell activation) (Miyahara et al., 2000).”
InfluentialPoleni, P.-E., Etienne, S., Velot, É., Netter, P., & Bianchi, A. (2010) · PPAR Research · doi:10.1155/2010/635912 · Cited by 30
“PPAR agonists can also repress the synthesis of extracellular matrix components in quite a lot of cell types, such as collagen synthesis by thiazolidinediones in mesangial cells from diabetic rats [23] and Wy14643 in hepatic stellate cells from rats with cholestatic liver fibrosis [24].”
BackgroundResultPeroxisome Proliferator‐Activated Receptors in HCV‐Related Infection
Dharancy, S., Lemoine, M., Mathurin, P., Serfaty, L., & Dubuquoy, L. (2009) · PPAR Research · doi:10.1155/2009/357204 · Cited by 24
“HSC activation is reversed by treatment with PPARγ agonists in vitro, suggesting antifibrogenic activity [38, 39].”
Penas, F., Cevey, Á. C., Siffo, S., Mirkin, G. A., & Goren, N. (2016) · Experimental Parasitology · doi:10.1016/j.exppara.2016.09.015 · Cited by 24
Miyoshi, M., Kakinuma, S., Kamiya, A., Tsunoda, T., Tsuchiya, J., Sato, A., Kaneko, S., Nitta, S., Kawai‐Kitahata, F., Murakawa, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37430-9 · Cited by 24
Palmitoylethanolamide Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis in Rats
Ohara, M., Ohnishi, S., Hosono, H., Yamamoto, K., Fu, Q., Maehara, O., Suda, G., & Sakamoto, N. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00709 · Cited by 27
Schnabl, B., Hu, K., Mühlbauer, M., Hellerbrand, C., Stefanovic, B., Brenner, D. A., & Schölmerich, J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.043 · Cited by 31
Jiang, J., van Ertvelde, J., Ertaylan, G., Peeters, R., Jennen, D. G. J., de Kok, T. M. C. M., & Vinken, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03583-4 · Cited by 26
Jia, S., Liu, X., Li, W., Xie, J., Yang, L., & Li, L. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000438567 · Cited by 23
Emerging physiological and pathological roles of MeCP2 in non-neurological systems
Wang, J., Xiao, Y., Liu, C., Huang, Y., Petersen, R. B., Zheng, L., & Huang, K. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2021.108768 · Cited by 23
Xu, Y., Farmer, S. R., & Smith, B. D. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703652200 · Cited by 24
Role of PNPLA3 in Hepatic Stellate Cells and Hepatic Cellular Crosstalk
Martins, M. C., Dixon, E. D., Lupo, G., Claudel, T., Trauner, M., & Rombouts, K. (2024) · Liver International · doi:10.1111/liv.16117 · Cited by 28
“Its expression was diminished upon activation when concomitantly AP-1 and NF-KB activities increased [51].”
Prevention of in vitro hepatic stellate cells activation by the adenosine derivative compound IFC305
Velasco-Loyden, G., Pérez‐Carreón, J. I., Agüero, J. F. C., Romero, P. C., Vidrio, S., Martínez-Pérez, L., Yañez-Maldonado, L., Hernández-Muñoz, R. E., Macías‐Silva, M., & de Sánchez, V. C. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.08.017 · Cited by 22
Ezhilarasan, D., & Najimi, M. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30915 · Cited by 26
“Previous studies have found decreased peroxisome proliferator‐activated receptor gamma (PPARγ) signaling in liver during HSC activation (Miyahara et al., 2000; X. X. Ni et al., 2021).”
BackgroundAlatas, F. S., Matsuura, T., Pudjiadi, A. H., Wijaya, S., & Taguchi, T. (2020) · Pediatric Gastroenterology Hepatology & Nutrition · doi:10.5223/pghn.2020.23.4.346 · Cited by 24
“Experiments have indicated that PPAR-γ ligands inhibit proliferation and activation of HSCs in vitro, and prevent fibrogenesis in experimental liver injury [1,20-22].”
BackgroundMondal, S. A., Sathiaseelan, R., Mann, S. N., Kamal, M., Luo, W., Saccon, T. D., Isola, J. V. V., Peelor, F. F., Li, T., Freeman, W. M., et al. (2022) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00256.2022 · Cited by 21
Rojkind, M., & Reyes‐Gordillo, K. (2009) · Wiley eBooks · doi:10.1002/9780470747919.ch28 · Cited by 21
Developing strategies for liver fibrosis treatment
Murphy, F. R., Arthur, M. J. P., & Iredale, J. P. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.11.1575 · Cited by 20
“PPAR-γ ligands reduce fibrotic and inflammatory actions of activated HSC [36,37].”
BackgroundHepatic stellate cells and alcoholic liver disease
Vera, M., & Nieto, N. (2006) · Revista Española de Enfermedades Digestivas · doi:10.4321/s1130-01082006000900005 · Cited by 26
Lan, T., Li, P., Zhang, S.-J., Liu, S.-Y., Zeng, X.-X., Chai, F., Tong, Y., Mao, Z.-J., & Wang, S. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155477 · Cited by 22
Zhou, Y., Jia, X., Zhou, M., & Liu, J. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.01.018 · Cited by 20
González-Cuevas, J., Bueno‐Topete, M. R., & Armendáriz‐Borunda, J. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04398.x · Cited by 19
Lecarpentier, Y., Schussler, O., CLAES, V. A., & Vallée, A. (2017) · Nuclear Receptor Research · doi:10.11131/2017/101299 · Cited by 21
“In human fibrotic diseases, PPARγ expression is diminished such as in lung [176], liver [164], kidney [165] and scarring alopecia [177].”
BackgroundHayashida, M., Hashimoto, K., Ishikawa, T., & Miyamoto, Y. (2019) · International Journal of Experimental Pathology · doi:10.1111/iep.12306 · Cited by 20
Novel targeted therapies for the management of liver fibrosis
Trivella, J. P., Martin, P. B., & Carrion, A. F. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1735350 · Cited by 22
Hepatic Fibrosis and Cirrhosis
Rockey, D. C., & Friedman, S. L. (2006) · Elsevier eBooks · doi:10.1016/b978-1-4160-3258-8.50011-5 · Cited by 36
Guo, Y., Leng, X.-S., Li, T., Peng, J.-R., Song, S., Xiong, L.-F., & Qin, Z.-Z. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i30.4735 · Cited by 21
Hu, S., Ai, Y., Hu, C., Bawa, F. N. C., & Xu, Y. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101372 · Cited by 23
“31 Interestingly, our previous studies illustrated that hepatocyte activating transcription factor (ATF3) plays a preventative role in the progression of MAFL to MASH by modulating FAO through HNF4 a .”
Sinagra, T., Tamburella, A., Urso, V., Siarkos, I., Drago, F., Bucolo, C., & Salomone, S. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.013 · Cited by 18
“In order to elucidate whether or not PPARg receptor stimulation was related to the observed inhibitory effect of thiazolidinediones on vascular contraction, we used GW9662, a PPARg antagonist [26,27].”
MethodRamani, K., & Tomasi, M. L. (2012) · Hepatology · doi:10.1002/hep.25594 · Cited by 19
“Out of the known PPAR subtypes, PPARc is known to promote HSC quiescence and its expression and activity is significantly reduced during HSC activation.(2,6) This led us to first examine whether PPARc was involved in regulating MAT2A in HSCs.”
GATA binding protein 3 is correlated with leptin regulation of PPAR γ1 in hepatic stellate cells
Guan, W., Cheng, F., Wu, H., Cao, Q., Zhu, X., Fan, Y., Zhu, H., & Zhou, Y. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13002 · Cited by 20
“Our results showed that leptin response region existed between position 2333 and 2245 upstream of the transcription start site of mouse PPARc1 promoter and leptin exerted an inhibitory effect on the expression of PPARc1, a major subtype of PPARc in HSCs [14], thus contributing to HSC activation [15].”
BackgroundDifficulty with diagnosis of malignant pancreatic neoplasms coexisting with chronic pancreatitis
Leung, T., Lee, C., Wang, F.-C., Chen, H.-C., & Wang, H. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i32.5075 · Cited by 19
Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease
Kim, Y. S., Hurley, E., Park, Y., & Ko, S. (2023) · Intestinal Research · doi:10.5217/ir.2023.00039 · Cited by 17
“PPARs also have anti-inflammatory effects through reduction in nuclear factorκB dependent gene activation and inflammatory cytokines as well as anti-fibrotic effects.(87) Bezafibrate is an agonist of PPARα/γ and the efficacy of bezafibrate in combination with UDCA has been demonstrated in patients with primary biliary…”
BackgroundYamanaka, O., Miyazaki, K.-I., Kitano, A., Saika, S., Nakajima, Y., & Ikeda, K. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2282 · Cited by 19
Hu, S., Bae, M., Park, Y., & Lee, J. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108452 · Cited by 18
15-Deoxy Prostaglandin J2 Enhances Allyl Alcohol-Induced Toxicity in Rat Hepatocytes
Maddox, J. F. (2003) · Toxicological Sciences · doi:10.1093/toxsci/kfh028 · Cited by 17
“It has been reported that metabolites of PGD2 inhibit protein synthesis in hepatic stellate cells (Miyahara et al., 2000); FIG.”
BackgroundGuo, X., Zheng, B., Wang, J., Zhao, T., & Zheng, Y. (2022) · Phytotherapy Research · doi:10.1002/ptr.7667 · Cited by 18
“…growth factor-β (TGF-β ) (Friedman et al., 1994) signaling pathway and dissipation of pro-mitotic platelet-derived growth factor-β (PDGF-β ) (Pinzani et al., 1996) as well as peroxisome proliferator-activated receptor-γ (PPAR γ ) (Galli et al., 2000; Marra et al., 2000; Miyahara et al., 2000).”
X‐box binding protein 1 is a novel key regulator of peroxisome proliferator‐activated receptor γ2
Cho, Y. M., Kwak, S., Joo, N., Kim, D. H., Lee, A., Kim, K., Seo, J. B., Jeong, S., & Kwon, O. (2014) · FEBS Journal · doi:10.1111/febs.13052 · Cited by 16
Cheng, J., Nakamura, H., Imanishi, H., Liu, W., Morisaki, T., Sugiyama, T., & Hada, T. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.07.133 · Cited by 16
The Role of Lipin-1 in the Regulation of Fibrogenesis and TGF-β Signaling in Hepatic Stellate Cells
Jang, C. H., Kim, K. M., Yang, J. H., Cho, S. S., Kim, S. J., Shin, S. M., Cho, I. J., & Ki, S. H. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw109 · Cited by 17
Laminin-521 promotes quiescence in isolated stellate cells from rat liver
Rohn, F., Kordes, C., Castoldi, M., Götze, S., Poschmann, G., Stühler, K., Herebıan, D., Benk, A. S., Geiger, F., Zhang, T., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.07.008 · Cited by 17
Protective effects of kaerophyllin against liver fibrogenesis in rats
Lee, T., Lin, Y., & Huang, Y. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2011.02625.x · Cited by 16
Lee, J. I., Paik, Y., Lee, K. S., Lee, J. W., Kim, Y., Jeong, S. W., Kwon, K. S., Lee, D. H., Kim, H. G., Shin, Y. W., et al. (2007) · Histochemistry and Cell Biology · doi:10.1007/s00418-007-0282-x · Cited by 16
“Experimental HSC activation, induced by platelet-derived growth factor (PDGF), the most potent mitogen for myoWbroblastic HSC (Pinzani et al. 1989, 1996), resulted in the decrement of PPAR- transcription (Marra et al. 2000; Miyahara et al. 2000; Galli et al. 2000).”
BackgroundBird, M. A., Lange, P. A., Schrum, L. W., Grisham, J. W., Rippe, R. A., & Behrns, K. E. (2002) · Surgery · doi:10.1067/msy.2002.122375 · Cited by 17
Self-citationMedical treatment of primary sclerosing cholangitis: What have we learned and where are we going?
Karlsen, T. H., Jørgensen, K. K., & Bergquist, A. M. (2024) · Hepatology · doi:10.1097/hep.0000000000001172 · Cited by 19
“[30] 36] One phase III randomized clinical trial investigating the effect on cholestatic pruritus of oral administration of bezafibrate 400 mg/d for 21 days to participants with either PSC or PBC reported improvement in liver blood tests as well as a significant reduction of pruritus in…”
PPAR and Liver Injury in HIV‐Infected Patients
Lemoine, M., Capeau, J., & Serfaty, L. (2009) · PPAR Research · doi:10.1155/2009/906167 · Cited by 19
“PPARγ has been shown to be expressed in quiescent hepatic stellate cells (HSCs) and its expression and activity are decreased during HSC activation in rats in vitro and in vivo [3, 28, 55].”
BackgroundChronic liver diseases: From development to novel pharmacological therapies: IUPHAR Review 37
Borrello, M. T., & Mann, D. A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15853 · Cited by 15
“The concept of reversion to a quiescent phenotype has been described in the literature for many years and initially focussed on reconstitution of PPAR γ signalling as a means to halt or reverse hepatic stellate cell activation (Miyahara et al., 2000; Yang et al., 2006).”
BackgroundHogan, C. M., Thatcher, T. H., Sapinoro, R., Gurell, M. N., Ferguson, H. E., Pollock, S. J., Jones, C., Phipps, R. P., & Sime, P. J. (2011) · PPAR Research · doi:10.1155/2011/318134 · Cited by 18
“GW9662 is a highly effective inhibitor of PPARγ-dependent processes including differentiation of osteoclasts and activation of hepatic stellate cells [47, 48].”
BackgroundMechanistic insights into the effects of SREBP1c on hepatic stellate cell and liver fibrosis
Su, S., Tian, H., Jia, X., Zhu, X., Wu, J., Zhang, Y., Chen, Y., Li, Z., & Zhou, Y. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15614 · Cited by 15
Balog, S., Fujiwara, R., Pan, S. Q., Elbaradie, K., Choi, H. Y., Sinha, S., Yang, Q., Asahina, K., Chen, Y., Li, M., et al. (2022) · Hepatology · doi:10.1002/hep.32793 · Cited by 15
“[20] As HSC activation is characterized by diminished adipogenesis regulation,[21] Aebp1 up‐regulation observed in Lrat+Thy1−Fbln2+ may contribute to the HSC‐to‐MFB shift through its anti‐adipogenesis actions.”
BackgroundSelf-citationCardoso, C. C. A., Paviani, E. R., Cruz, L. A., Guma, F. T. C. R., Borojević, R., & Guaragna, R. M. V. D. C. (2003) · Molecular and Cellular Biochemistry · doi:10.1023/a:1027356412399 · Cited by 14
“[37] demonstrated that HSC activation is associated with the reduction in PPAR-γ expression and PPAR-responsive element binding.”
BackgroundPPARγ ligands attenuate mesangial contractile dysfunction in high glucose
植田, 麻., Wakisaka, M., Ago, T., Kitazono, T., Nakamura, U., Yoshinari, M., Iwase, M., & Iida, M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00474.x · Cited by 14
“The induction of PPARcl at mRNA and protein levels by troglitazone [36] and the prevention of TNF-a–induced suppression in PPARcl mRNA by troglitazone, pioglitazone, and 15d-PGJ2 [28, 37] have been also reported.”
BackgroundHepatic Fibrosis and Cirrhosis
Rockey, D. C., & Friedman, S. L. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0881-3.00005-x · Cited by 22
Zhu, H., Bai, W., Wang, H.-T., Xie, S., Tao, K., Su, L., Liu, J., Yang, X., Li, J., Wang, Y.-C., et al. (2016) · PubMed Central · Cited by 22
Targeting the Wnt signaling pathway: the challenge of reducing scarring without affecting repair
Jarman, E. J., & Boulter, L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1718105 · Cited by 13
Suppressive Effect of Orthovanadate on Hepatic Stellate Cell Activation and Liver Fibrosis in Rats
Nishikawa, Y., Ohi, N., Yagisawa, A., Doi, Y., Yamamoto, Y., Yoshida, M., Tokairin, T., Yoshioka, T., Omori, Y., & Enomoto, K. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080261 · Cited by 13
Epigenetic mechanism of stellate cell trans-differentiation
Tsukamoto, H. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.11.002 · Cited by 13
“Recent studies highlight the importance of adipogenic regulation in maintenance of HSC quiescence and loss of this regulation in HSC MTD [7–9].”
BackgroundSelf-citationEffects of Dan-shao-hua-xian on expression of PPAR-gamma and NF-kappa B in rat liver fibrosis.
Wang, H.-Y., & Cheng, M.-L. (2008) · PubMed · Cited by 13
Tang, Y., Ma, N., Luo, H., Chen, S., & Yu, F. (2020) · The Journal of Biochemistry · doi:10.1093/jb/mvaa013 · Cited by 16
Endothelium-dependent vasomotor effects of telmisartan in isolated rat femoral arteries
Siarkos, I., Urso, V., Sinagra, T., Drago, F., & Salomone, S. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.10.010 · Cited by 12
Fuja, T. J., Probst-Fuja, M. N., & Titze, I. R. (2005) · Matrix Biology · doi:10.1016/j.matbio.2005.08.005 · Cited by 12
Nuclear receptor ligands in therapy of cholestatic liver disease
Sturm, E., Wagner, M., & Trauner, M. (2009) · Frontiers in bioscience · doi:10.2741/3529 · Cited by 12
“PPAR-α ligands are antifibrotic in cultured stellate cells (116, 117) and in experimental animals (118-120).”
BackgroundIlluminating liver fibrosis with vitamin D
Firrincieli, D., Braescu, T., Housset, C., & Chignard, N. (2013) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2013.10.004 · Cited by 12
“[4] Miyahara T, Schrum L, Rippe R, Xiong S, Yee Jr HF, Motomura K, et al.”
BackgroundQiao, H., Cao, Q., Fu, Y., Guan, W., Cheng, F., Wu, J., Jia, X., Chen, H., & Zhou, Y. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.09.001 · Cited by 12
Thiazolidinediones and hepatic fibrosis: don’t wait too long
Marra, F. (2006) · Gut · doi:10.1136/gut.2005.085399 · Cited by 11
Sorice, G. P., & Folli, F. B. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2009.04.058 · Cited by 11
“stellate cells [47–52].”
Wang, W., Yan, M., Ji, Q., Lu, J., Ji, Y., & Ji, J. (2015) · PeerJ · doi:10.7717/peerj.1362 · Cited by 11
“, 2004) and PPAR signaling pathways (Miyahara et al., 2000) were significantly suppressed during HSC activation, and both pathways were closely related to the proliferative phenotype of activated HSCs.”
BackgroundRosenberg, P. M., Sjöström, M., Söderberg, C., Kinnman, N., Stal, P. I., & Hultcrantz, R. W. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02486.x · Cited by 11
“Hepatic stellate cells from C57BL/6J and C57BL/6J N-CAM / mice were isolated based on a method previously described, with minor modifications (25).”
MethodMorphogen-related therapeutic targets for liver fibrosis
Fung, E., & Tsukamoto, H. (2015) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2015.05.017 · Cited by 11
“Activation of HSCs involves the coordination of multiple signaling events including down-regulation of PPARγ much like de-differentiation of mature adipocytes to preadipocytic fibroblasts [7,8].”
BackgroundSelf-citationHusain, H., Ahmad, R., Khan, A., Inamuddin, I., & Asiri, A. M. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.12.168 · Cited by 10
Kruse, M., Hopf-Jensen, S., Timke, C., Agricola, B., Sparmann, G. H., Schmid, A., Sipos, B., Arlt, A., & Schäfer, H. (2011) · International Journal of Cell Biology · doi:10.1155/2011/816791 · Cited by 10
“Similar results were found for hepatic stellate cells (HSCs) in vitro [20]; most of these experiments were carried out on cells for rat origin.”
Update on the Treatments of Non-Alcoholic Fatty Liver Disease (NAFLD)
Quercioli, A., Montecucco, F., & Mach, F. (2009) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x10909040261 · Cited by 11
“[184] Miyahara, T.”
BackgroundSun, Y., Yuan, X., Hu, Z., & Li, Y. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116730 · Cited by 10
Senescent cells in systemic aging: SASP heterogeneity, immune escape, and endocrine modulation
Qoura, L. A., Churov, A. V., Maltseva, O. N., Ерусланова, К. А., & Zeng, G. (2026) · Biogerontology · doi:10.1007/s10522-026-10449-6 · Cited by 12
“HNF4α is crucial for regulating FAO; its overexpression promotes lipolysis and FAO, while its loss has the opposite effect (Miyahara et al. 2000).”
López, C. A. M., Freiberger, R. N., Sviercz, F. A., Jarmoluk, P., Cevallos, C. G., Quarleri, J. F., & Delpino, M. V. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167084 · Cited by 9
Wang, B., Wu, Z., Li, W., Liu, G., & Tang, Y. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00473-8 · Cited by 9
Altered expression and function of hepatic natural killer T cells in obese and diabetic KK‐Ay mice
Yamagata, H., Ikejima, K., Takeda, K., Aoyama, T., Kon, K., Okumura, K., & Watanabe, S. (2012) · Hepatology Research · doi:10.1111/j.1872-034x.2012.01062.x · Cited by 10
Plasma membrane calcium ATPase isoform 3 expression in single cells isolated from rat liver
Delgado‐Coello, B., Bravo-Martínez, J., Sosa‐Garrocho, M., Briones-Orta, M. A., Macías‐Silva, M., & Mas‐Oliva, J. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0535-1 · Cited by 9
“Markers for HSC and EC were amplified using 25 cycles [22, 23].”
BackgroundMethodInfluentialHistopathological Characteristics of Ito Cells and Kupffer Cells in the Feline Liver
Uetsuka, K., NISHIKAWA, S., Yasoshima, A., Nakayama, H., & Doi, K. (2006) · Journal of Veterinary Medical Science · doi:10.1292/jvms.68.235 · Cited by 9
Metabolic reprogramming and cell fate regulation in alcoholic liver disease
Tsukamoto, H. (2015) · Pancreatology · doi:10.1016/j.pan.2015.03.003 · Cited by 10
Self-citationQu, C., Leung, S. W. S., Vanhoutte, P. M., & Man, R. Y. K. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.09.015 · Cited by 9
Anti- and Protumorigenic Effects of PPARγin Lung Cancer Progression: A Double-Edged Sword
Li, H. Y., Weiser‐Evans, M. C. M., & Nemenoff, R. A. (2012) · PPAR Research · doi:10.1155/2012/362085 · Cited by 11
“[113] T.”
Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology
Yoon, I. C., & Eun, J. R. (2019) · Journal of Yeungnam Medical Science · doi:10.12701/yujm.2019.00171 · Cited by 9
“Moreover, PPAR-γ inhibits HSC activation and increases adiponectin levels [19,20].”
BackgroundA Selective PPARγ Modulator Reduces Hepatic Fibrosis
McVicker, B. L., Hamel, F. G., Simpson, R. L., & Bennett, R. G. (2020) · Biology · doi:10.3390/biology9070151 · Cited by 10
Sugihara, T. (2025) · Yonago acta medica · doi:10.33160/yam.2025.05.002 · Cited by 8
Demethylbellidifolin Inhibits Proliferation and Activation ofHepatic Stellate Cells
Li, J. F., Lu, G. F., & Zou, Y. (2011) · Journal of Investigative Surgery · doi:10.3109/08941939.2011.568593 · Cited by 8
“by PPAR-γ have been reported in HSC [9].”
BackgroundA modified in vitro tool for isolation and characterization of rat quiescent islet stellate cells
Li, W., Zhou, Y., Wang, X., Cai, M., Gao, F., Carlsson, P., & Sun, Z. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.111617 · Cited by 8
The role of retinoic acid receptors in activated hepatic stellate cells
Mezaki, Y., Morii, M., Hebiguchi, T., Yoshikawa, K., Yamaguchi, N., Yoshino, H., & Senoo, H. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.04.045 · Cited by 10
“Since diminished Rara mRNAs in activated HSCs were first reported [16–18], the main strategies for prevention of liver fibrogenesis have shifted to target another nuclear receptor family member, peroxisome proliferator-activated receptor (PPAR)c [25–27].”
BackgroundZhao, B., Hu, M., Wu, H., Ren, C., Chen, J., Zhang, X., & Cui, S. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3578 · Cited by 8
“ECM proteins, such as collagen I and III, were negative, which are similar to a report by other researchers (44).”
Role of metabolic nuclear receptors in acute liver injury and drug-induced hepatotoxicity
Nie, L., Yan, N., Gonzalez, F. J., Hao, H., & Yan, T. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107942 · Cited by 7
Nonalcoholic Steatohepatitis: Lessons from Different Diet-induced Animal Models
Souza‐Mello, V. (2014) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2014.01.00014 · Cited by 8
“Besides, therapy with PPAR-gamma agonist has been linked with inhibition of cell proliferation and collagen expression in HSCs in vitro and in vivo [90,91], making PPARgamma agonists a potential approach to treat NASH.”
BackgroundKim, K., Lim, Y., Kim, K.-M., Yoon, J., & Lee, H.-S. (2005) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2005.06.003 · Cited by 8
Molecular mechanism of stellate cell activation and therapeutic strategy for liver fibrosis
Kawada, N. (2004) · Comparative Hepatology · doi:10.1186/1476-5926-2-s1-s3 · Cited by 11
Liu, X., Zhang, M., Zhang, H., Zhao, A., Sun, J., & Tang, W. (2019) · Europe PMC (PubMed Central) · doi:10.12122/j.issn.1673-4254.2019.05.10 · Cited by 7
An overview of recent treatment options for primary sclerosing cholangitis
Mousavere, I., Kalampokis, G., Fousekis, F., Karayiannis, P., Baltayiannis, G., & Christodoulou, D. (2023) · Annals of Gastroenterology · doi:10.20524/aog.2023.0834 · Cited by 9
“Like the FXR, PPARs have pleiotropic effects and interact with bile acid nuclear receptors, leading to anti-inflammatory and antifibrotic effects [64].”
BackgroundLee, B. J., Lee, H. S., Kim, C. D., Jung, S. W., Seo, Y. S., Kim, Y. S., Jeen, Y. T., Chun, H. J., Um, S. H., Lee, S. W., et al. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.2.262 · Cited by 6
“PPARγ also mediate antifibroic effects in HSCs and PaSCs.(29-33) Previous studies using thiazolidinedione derivatives have shown that troglitazone decreased proliferation of PaSCs and the expression of α-SMA by the modulation of PPARγ expression(31) or PPARγ independent manners.”
BackgroundDornas, W., Glaise, D., Bodin, A., Sharanek, A., Burban, A., Guillou, D. L., Robert, S., Dutertre, S., Aninat, C., Corlu, A., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27175 · Cited by 6
“…partially mediated by the cooperative action of a panel of putative adipogenic transcription factors expressed in quiescent HSC and their coordinated depletion in activated HSC, which is in agreement with the results of previous studies (Miyahara et al., 2000; She, Xiong, Hazra, & Tsukamoto, 2005).”
ResultThe Effects of Freshwater Clam (Corbicula fluminea) Extract on Activated Hepatic Stellate Cells
Lee, S.-L., Hsu, W., Tu, C.-M., Wang, W., Yang, C., Lee, H.-K., & Chin, T. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6065168 · Cited by 6
Metadata
- Authors
- Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Motomura, K., Anania, F. A., Willson, T. M., & Tsukamoto, H.
- Affiliations
- University of Southern California (US)
- University of North Carolina at Chapel Hill (US)
- University of California, Los Angeles (US)
- University of Maryland, College Park (US)
- Corresponding author
- Tsukamoto, Hidekazu
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-11
- Volume
- 275
- Issue
- 46
- Pages
- 35715-35722
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2025657436
- Cited by
- 473
- References
- 56
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 8 · 2023: 9 · 2022: 12 · 2021: 17 · 2020: 18 · 2019: 14 · 2018: 14 · 2017: 19 · 2016: 16 · 2015: 22 · 2014: 21 · 2013: 17 · 2012: 25
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 7274 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- U.S. Department of Veterans Affairs
- University of Southern California (DK48522)
- National Institutes of Health (5k08dk002450-05, AA10459)
- National Institute on Alcohol Abuse and Alcoholism (AA10459, R37AA006603, R37-AA-06603, P50AA011999)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-02450)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- peroxisome proliferator-activated receptors, PPARγ, hepatic stellate cell activation, liver fibrosis, cholestatic liver fibrosis, bile duct ligation, PPAR ligands, collagen synthesis, PPAR-responsive element, TNF-α, matrix metalloproteinase-3
- MeSH terms
- Rosiglitazone, Animals, Cell Survival, Cells, Cultured, Collagen, DNA, Gene Expression Regulation, Liver, Liver Cirrhosis, Biliary, Liver Cirrhosis, Experimental, Male, Promoter Regions, Genetic, Protein Binding, Pyrimidines, RNA, Messenger, Thiazoles, Transcription Factors, Tumor Necrosis Factor-alpha, Prostaglandin D2, Rats, Wistar, Receptors, Cytoplasmic and Nuclear, Protein Isoforms, Thiazolidinediones, Cell Size, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.